Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement From EnVVeno Medical's VenoValve(R) Pivotal Trial to Be Presented Today at the 46th Annual Charing Cross Symposium

Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Pa

AccesswireApr 24 18:15

New Topline Efficacy Data From the EnVVeno Medical VenoValve(R) Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today an

AccesswireApr 16 21:00

EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValvePMA application seeking FDA approval for the VenoValve on track to be filed

AccesswireApr 9 20:45

EnVVeno Medical(NVNO.US) Officer Sells US$51,837.48 in Common Stocks

$enVVeno Medical(NVNO.US)$ Officer Alavi Hamed sold 8,334 shares of Common Stocks on Mar 13, 2024 at an average price of $6.22 for a total value of $51,837.48.Source: Announcement What is statement of

Futu NewsMar 16 08:40

EnVVeno Medical to Participate in the Virtual Investor Lunch Break: The EnVVeno Opportunity

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation

AccesswireMar 15 21:00

EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial

EnVVeno Medical (NVNO) announced "positive topline efficacy data showing significant clinical improvement" from the US pivotal trial for VenoValve, a surgical replacement being developed for severe ch

MT NewswiresMar 7 04:52